Dysregulative lymphoma theory revisited; what can we learn from cytokines, CD classes and genes?

Anticancer Research

Volumn 21, Issue 5, 2001, Pages 3653-3661

  Krueger, Gerhard R F ^a   Nguyen, Andy N D ^a   Uthman, Margaret ^a   Brandt, Michael E ^a   Buja, L Maximilian ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

CD Markers; Cytogenetics; Cytokines; Malignant lymphomas

Indexed keywords

ANTIGEN; CYTOKINE;

ARTICLE; B CELL LYMPHOMA; COMPUTER SIMULATION; CYTOGENETICS; HUMAN; IMMUNE DEFICIENCY; IMMUNOSTIMULATION; LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; T CELL LYMPHOMA;

ANIMALS; ANTIGENS, CD; CYTOKINES; HUMANS; LYMPHOMA;

EID: 0035570870     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (121)

1. Molecular genetics and cytogenetics of hematopoietic malignancies
2. Molecular mechanisms of mutagenesis and multistage carcinogenesis
3. Viral carcinogenesis
4. Tests of carcinogenic substances in relation to production of mutations in drosophila melanogaster
5. The gene
6. Mutation rate following treatment of neurospora with 20-methylcholanthrene and 1,2,5,6-dibenzanthracene in tween-80
7. Epstein-Barr virus and its association with human disease: An overview
8. Epstein-Barr virus as an etiological agent in the pathogenesis of lymphoproliferative and aproliferative diseases in immune deficient patients
9. A unifying concept of viral immunopathogenesis of proliferative and aproliferative diseases (working hypothesis)
10. Cell cycle checkpoints and growtharrest genes activated by genotoxic stress
11. Cytogenetics and neoplasia
12. Malignant lymphomas and plasmacytosis in mice under chronic immunosuppression and persistent antigenic stimulation
13. The significance of immunosuppression and antigenic stimulation in the development of malignant lymphomas
14. Sequential changes of T and B cells, virus antigen expression and primary histologic diagnosis of virus induced lymphomagenesis in mice
15. T and B cell determination in various lymphoid tissues of mice during N-nitrosobutylurea (NBU) leukemogenesis
16. Host response during the latent period and the growth of an immunolgically induced mouse lymphoma
17. Differentiation block of prethymic lymphocytes during Moloneyvirus induced lymphoma development associated with a thymic epithelial defect
18. Quantitative light and electron microscopic changes in thymic reticular epithelial cells during Moloneyvirus induced lymphoma development
19. Chronic immunosuppression and lymphomagenesis in man and mice
20. Abnormal variation of the immune system as related to cancer
21. Malignant T cell lymphomas and immune deficiency: A computer-assisted model
22. Diagnosis and differential diagnosis of progressive lymphoproliferation and malignant lymphoma in persistent active herpesvirus infection
23. Immunological dysregulation of lymph nodes in AIDS patients
24. Atypical lymphoproliferative disorders
25. Pathological findings in human autoimmune lymphoproliferative syndrome
26. Pathology of lymphoproliferative disorders in HIV infection
27. Revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
28. A relational database for diagnosis of hematopoietic neoplasms using immunophenotyping by flow cytometry
29. Appendix A. Human leukocyte surface antigens
30. Appendix B. Cytokines and cytokine receptors
31. Molecular biology of lymphoid neoplasms
32. Cytogenetic changes in the progression of lymphoma
33. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and cladribine induced remission
34. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: Costimulation with IL-2 results in a highly immunogenic phenotype
35. Serum levels of tetranectin, intercellular adhesion molcule-1 and interleukin-10 in B-chronic lymphocytic leukemia
36. Release of interleukin-6 in cultured B-chronic lymphocytic leukaemia cells is associated with both activation and cell death via apoptosis
37. Reduced IL-4 and interferon-gamma (IFN-gamma) expression by CD4 T cells in patients with chronic lymphocytic leukaemia
38. Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders
39. Clinico-biological implications of increased serum levels of interleukin-8 in B-cell chronic lymphocytic leukemia
40. Cytokines in malignant lymphomas: Review and prospective evaluation
41. Classification of small B cell lymphoid neoplasms using a paraffin section immunohistochemical panel
42. Interleukin 3 is a growth factor for human follicular B cell lymphoma
43. In vitro and in vivo biological effects of interleukin-3 (IL-3) in follicular low-grade lymphoma
44. Interleukin-2 and interferon-gamma production in follicular lymphomas
45. Role of autologous CD4+ T cell clones in human B non-Hodgkin's lymphoma: Aborted activation and G1 blockade induced by cell-cell contact
46. Involvement of the bcl-2 gene in human follicular lymphoma
47. M. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas
48. Sequential bcl-2 and c-myc oncogene rearrangements associated with the clinical transformation of non-Hodgkin's lymphomas
49. Clinical significance of the t(14;18) and BCL 2 overexpression in follicular large cell lymphoma
50. Clinicopathologic reassessment of primary cutaneous B cell lymphomas with immunophenotyic and molecular genetic characterization
51. The IgG Fc receptor, FcgammaRIIB, is a target for deregulation by chromosomal translocation in malignant lymphoma
52. Follicular lymphomas' BCL-2/IgH junctions contain templated nucleotide insertions: novel insights into the mechanism of t(14;18) translocation
53. p53 mutation is associated with progression in follicular lymphomas
54. Somatic mutation of the 5′ noncoding region of the Bcl-6 gene is associated with intraclonal diversity and clonal selection in histological transformation of follicular lymphoma
55. Up-regulation of BOB.1/OBF.1 expression in normal germinal center B cells and germinal center-derived lymphomas
56. Mantle cell lymphoma proliferates upon IL-10 in the CD40 system
57. Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4
58. Bcl-1/cyclin D1 in malignant lymphoma
59. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells
60. Role of interleukin-6 in the pathogenesis of multiple myeloma
61. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
62. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as a mechanism of tumor propagation in multiple myeloma
63. Molecular basis of human B-cell neoplasia
64. Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma
65. Marker band in one chromosome 14 from Burkitt's lymphoma
66. Alternative involvement of two cytogenetically distinguishable breakpoints on chromosome 8 in Burkitt's lymphoma associated translocations
67. Epidemiologic and immunologic considerations on the pathogenesis of Burkitt's tumor
68. Promotion of IL-8, IL-10, TNF alpha and TNF beta production by EBV infection
69. Isolation of human interleukin-10 promoter: Characterization of the promoter activity in Burkitt's lymphoma cell lines
70. Interleukin-13 gene expression by malignant and EBV-transformed human B lymphocytes
71. Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction
72. IL-6 and IL-6 receptor expression in Burkitt's lymphoma and lymphoblastoid cell lines: Promotion of IL-6 receptor expression by EBV
73. Epstein-Barr virus-dependent lymphoproliferative disease: Critical role of IL-6
74. Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia
75. Interleukin-15: A novel cytokine with regulatory properties on normal and neoplastic B lymphocytes
76. Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia
77. Hairy cell leukemia is characterized by clonal chromosomal abnormalities clustered to specific regions
78. Proliferation and cytogenetic analysis of hairy cell leukemia upon stimulation via the CD40 antigen
79. del(17)(q25) in a patient with hairy cell leukemia: A new clonal chromosome abnormality
80. Involvement of the CCND1 gene in hairy cell leukemia
81. Hairy cell leukemia with translocation (11;20)(q13;q11) and overexpression of cyclin D1
82. Phenotypical heterogeneity of CD4+CD8+ double-positive chronic T lymphocytic leukemia
83. Circulating levels of cytokines and soluble cytokine receptors in various T-cell malignancies
84. An HTLV-1 carrier who developed CD4+ T-CLL expressed the IL-2 receptor beta chain alone without expressing the alpha chain
85. Interleukin-2 prevents programmed cell death in chronic lymphocytic leukemia cells
86. Interleukin-7 (IL-7)-induced proliferation of CD8+ T-chronic lymphocytic leukemia cells
87. Peripheral T cell lymphomas. Immunoregulatory cytokine (interleukin-2, interleukin-4, and interferon-gamma) abnormalities and autologous mixed lymphocyte reaction
88. Differential cytokine expression in EBV positive peripheral T cell lymphomas
89. Junctional heterogeneity and pathogenic significance of interleukin-6 in B-cell lymphomas
90. Cell dynamics and expression of tumor necrosis factor (TNF)-alpha, interleukin-6, and TNF-receptors in angioimmunoblastic lymphadenopathy-type T cell lymphoma
91. Analysis of immunoglobulin, T cell receptor and ber rearrangement in human malignant lymphoma and Hodgkin's disease
92. Interleukin 4 and interferon-gamma expression of the dermal infiltrate in patients with erythroderma and mycosis fungoides. An immunohistochemical study
93. Epidermal interferon-gamma inducible protein-10 (IP-10) and monokine induced by gammainterferon (Mig) but not IL-8 mRNA expression is associated with epidermotropism in cutaneous T cell lymphomas
94. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells
95. Immunohistochemical expression of IL-10 in mycosis fungoides
96. Progression of mycosis fungoides is associated wwith increasing cutaneous expression of interleukin-10 mRNA
97. Cytokine profile of tumor cells in mycosis fungoides: Successful treatment with intra-lesional interferon-gamma combined with chemotherapy
98. Interleukin-7 receptor expression in cutaneous T-cell lymphomas
99. Expression of the CD4+ cell-specific chemoattractant interleukin-16 in mycosis fungoides
100. Rearrangement of the T-cell receptor delta chain gene in T-cell lymphomas with a mature phenotype
101. Recurrent structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sezary syndrome
102. Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN
103. p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides
104. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: Tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines
105. Human interleukin-10 expression in T/natural killer-cell lymphomas: Association with anaplastic large cell lymphomas and nasal natural killer-cell lymphomas
106. Angiocentric lymphoma with granulomatous panniculitis in the skin expressing natural killer cell and large granular T-cell phenotypes
107. Aggressive pleomorphic CD2+, CD3-, CD56+ lymphoma with t(5:9)(q31;q34) abnormality
108. Unbalanced X; autosome translocation (X;18)(q13;p11) in a case of aggressive natural killer non-Hodgkin lymphoma
109. A man with natural killer cell lymphoma showing 46,XX and deletion 6q
110. Chromosomal translocations are common in natural killer-cell lymphoma/leukemia as shown by special karyotyping
111. The control of growth and differentiation in normal and leukemic blood cells
112. Cancer dormancy: Isolation and characterization of dormant lymphoma cells
113. NCI sponsored study of classifications of non-Hodgkin's lymphomas
114. BCL-1 (PRAD-1/cyclin D-1) overexpression distinguishes the blastoid variant of mantle cell lymphoma from B-lineage lymphoblastic lymphoma
115. Tumour necrosis factor altha (TNF alpha) and leukemic cells: Secretion and response
116. The IL-6 gene expression by leukemic cells from acute lymphoblastic leukemia common and T type modulation of IL-6 production by TNF
117. Identification of del(6) (q21;q25) as a recurring chromosomal abnormality in putative NK cell lymphoma/leukemia